These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 24619073

  • 1. Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models.
    Cao S, Durrani FA, Tóth K, Rustum YM.
    Br J Cancer; 2014 Apr 02; 110(7):1733-43. PubMed ID: 24619073
    [Abstract] [Full Text] [Related]

  • 2. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
    Cao S, Durrani FA, Rustum YM.
    Clin Cancer Res; 2004 Apr 01; 10(7):2561-9. PubMed ID: 15073137
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.
    Azrak RG, Cao S, Pendyala L, Durrani FA, Fakih M, Combs GF, Prey J, Smith PF, Rustum YM.
    Biochem Pharmacol; 2007 May 01; 73(9):1280-7. PubMed ID: 17239826
    [Abstract] [Full Text] [Related]

  • 4. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
    Chintala S, Tóth K, Cao S, Durrani FA, Vaughan MM, Jensen RL, Rustum YM.
    Cancer Chemother Pharmacol; 2010 Oct 01; 66(5):899-911. PubMed ID: 20066420
    [Abstract] [Full Text] [Related]

  • 5. Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
    Bhattacharya A, Tóth K, Durrani FA, Cao S, Slocum HK, Chintala S, Rustum YM.
    Neoplasia; 2008 Aug 01; 10(8):857-65. PubMed ID: 18670644
    [Abstract] [Full Text] [Related]

  • 6. Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.
    Azrak RG, Yu J, Pendyala L, Smith PF, Cao S, Li X, Shannon WD, Durrani FA, McLeod HL, Rustum YM.
    Mol Cancer Ther; 2005 May 01; 4(5):843-54. PubMed ID: 15897249
    [Abstract] [Full Text] [Related]

  • 7. Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis.
    Yin MB, Li ZR, Tóth K, Cao S, Durrani FA, Hapke G, Bhattacharya A, Azrak RG, Frank C, Rustum YM.
    Oncogene; 2006 Apr 20; 25(17):2509-19. PubMed ID: 16518418
    [Abstract] [Full Text] [Related]

  • 8. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.
    Health Technol Assess; 2008 May 20; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.
    Tsuji K, Yasui H, Onozawa Y, Boku N, Doyama H, Fukutomi A, Yamazaki K, Machida N, Todaka A, Taniguchi H, Tsushima T, Yokota T.
    Jpn J Clin Oncol; 2012 Aug 20; 42(8):686-90. PubMed ID: 22693245
    [Abstract] [Full Text] [Related]

  • 14. Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.
    Na YS, Kim SM, Jung KA, Yang SJ, Hong YS, Ryu MH, Ro S, Cho DH, Kim JC, Jin DH, Lee JS, Kim TW.
    Oncol Rep; 2010 Dec 20; 24(6):1509-14. PubMed ID: 21042746
    [Abstract] [Full Text] [Related]

  • 15. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
    Ulrich-Pur H, Kornek GV, Fiebiger W, Gedlicka C, Raderer M, Lenauer A, Depisch D, Lang F, Pidlich J, Scheithauer W.
    Ann Oncol; 2001 Sep 20; 12(9):1269-72. PubMed ID: 11697839
    [Abstract] [Full Text] [Related]

  • 16. Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
    Sheikh HY, Valle JW, Palmer K, Sjursen A, Craven O, Wilson G, Swindell R, Saunders MP.
    Br J Cancer; 2007 Jan 15; 96(1):38-43. PubMed ID: 17213824
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.